Literature DB >> 1999506

Biology of basal cell carcinoma (Part I).

S J Miller1.   

Abstract

Basal cell carcinoma is the most common malignancy in humans. Although rarely metastatic, it is capable of significant local destruction and disfigurement. This two-part article reviews the current understanding of basal cell carcinoma biology. Part I examines significant clinical, histologic, and ultrastructural features that relate to invasive potential. Genetic characteristics, including tumor growth rate, chromosomal abnormalities, and oncogene presence, are discussed, and expression of important cell and matrix proteins, including keratin, fibronectin, and HLA antigens, are reviewed. Further topics to be explored in Part II include host immunologic responses, theories of pathogenesis, and valuable second-line therapeutic regimens for treatment of multiple cancers.

Entities:  

Mesh:

Year:  1991        PMID: 1999506     DOI: 10.1016/0190-9622(91)70001-i

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  49 in total

1.  Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions.

Authors:  Juliet A Williams; Oivin M Guicherit; Beatrice I Zaharian; Yin Xu; Ling Chai; Hynek Wichterle; Charlene Kon; Christine Gatchalian; Jeffery A Porter; Lee L Rubin; Frank Y Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-04       Impact factor: 11.205

2.  Comparison of the expression of p53, p21, Bax and the induction of apoptosis between patients with basal cell carcinoma and normal controls in response to ultraviolet irradiation.

Authors:  M Murphy; M J E M F Mabruk; P Lenane; A Liew; P McCann; A Buckley; C O Flatharta; D Hevey; P Billet; W Robertson; S Javed; M Leader; E Kay; G M Murphy
Journal:  J Clin Pathol       Date:  2002-11       Impact factor: 3.411

3.  High levels of patched gene mutations in basal-cell carcinomas from patients with xeroderma pigmentosum.

Authors:  N Bodak; S Queille; M F Avril; B Bouadjar; C Drougard; A Sarasin; L Daya-Grosjean
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

4.  Relationship of treatment delay with surgical defect size from keratinocyte carcinoma (basal cell carcinoma and squamous cell carcinoma of the skin).

Authors:  Melody J Eide; Martin A Weinstock; Raymond G Dufresne; Suleka Neelagaru; Patricia Risica; Gary J Burkholder; David Upegui; Katharine A Phillips; Bruce K Armstrong; Leslie Robinson-Bostom
Journal:  J Invest Dermatol       Date:  2005-02       Impact factor: 8.551

5.  Role of PTCH and p53 genes in early-onset basal cell carcinoma.

Authors:  H Zhang; X L Ping; P K Lee; X L Wu; Y J Yao; M J Zhang; D N Silvers; D Ratner; R Malhotra; M Peacocke; H C Tsou
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

6.  5 years review of periocular basal cell carcinoma and proposed follow-up protocol.

Authors:  S F Ho; L Brown; M Bamford; R Sampath; J Burns
Journal:  Eye (Lond)       Date:  2012-11-16       Impact factor: 3.775

7.  Giant Basal Cell Carcinomas Express Neuroactive Mediators and Show a High Growth Rate: A Case-Control Study and Meta-Analysis of Etiopathogenic and Prognostic Factors.

Authors:  Mohammad-Ali Yazdani Abyaneh; Peter Engel; Andrzej Slominski; Bruce Ragsdale; Richard Agag; Daniel Cramer; J Andrew Carlson
Journal:  Am J Dermatopathol       Date:  2017-03       Impact factor: 1.533

Review 8.  [Basal cell carcinoma and rare form variants].

Authors:  J Liersch; J Schaller
Journal:  Pathologe       Date:  2014-09       Impact factor: 1.011

9.  The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma.

Authors:  Mara Ozolins; Hywel C Williams; Sarah J Armstrong; Fiona J Bath-Hextall
Journal:  Trials       Date:  2010-04-21       Impact factor: 2.279

10.  Linkage of epidermolysis bullosa simplex to keratin gene loci.

Authors:  K E McKenna; A E Hughes; E A Bingham; N C Nevin
Journal:  J Med Genet       Date:  1992-08       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.